Group control-after intervention. by Nan Tang (642590)

Subjects:

Group SFA-before intervention. by Nan Tang (642590)

Subjects:

Lost cases. by Nan Tang (642590)

Subjects:

Group control-before intervention. by Nan Tang (642590)

Subjects:

Patient satisfaction with SFA intervention(%). by Nan Tang (642590)

Subjects:

Pre-Experiment. by Nan Tang (642590)

Subjects:

Group SFA-after intervention. by Nan Tang (642590)

Subjects:

Effects of GJE extract treatment decreased protein expression of MMP-12, α-SMA, IL-13, and TGF-β1 levels. by Natnicha Suttawong (22367172)

Tax1bp1-deficiency decreases the frequency of microabscess formation and lymphocyte depletion during <i>L. monocytogenes</i> infection. by Jeffrey Chin (22538086)

Flow diagram showing number of subjects included in the study population. by Jung-Tae Kim (8997767)

Subjects:

This is the raw data used for this study. by James M. Friedman (22522150)

Subjects:

Pre-operative versus post-operative symptoms. by James M. Friedman (22522150)

Subjects:

Patient Demographics. by James M. Friedman (22522150)

Subjects:

Diagnostic Criteria for Human Disharmony Loop. by James M. Friedman (22522150)

Subjects:

Inhibition of LDHA leads to decreased ATP, reduced AKT phosphorylation, and enhanced chemotherapy sensitivity to LBP in A549 and NCL-H1975 cells. by Siyu Yuan (7425719)

Subjects:

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P_i-induced VSMCs. …”

RcbA and RcbB co-operatively decrease motility independent of CaCl₂ concentration. by Shobnom Mustaree (21728815)

<i>Porphyromonas gingivalis</i> LPS pretreated by ozone ultrafine bubble water induces decreased TLR2 activation. by Mana Endo (22430706)

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”